Ibrutinib combined with venetoclax is being tested as a first-line treatment for chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). This study shows that fixed-duration ibrutinib plus venetoclax provides deep, durable responses and significant time without progression for individuals with CLL, including those with high-risk markers.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data from the CAPTIVATE study.
Read the full article on CLL Society's website at: [ Ссылка ]
__________________________________________________________________________________________
CLL Society Website: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
